New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control - Roche Holding
Benzinga Roche Group Holdings AG'sRHHBYdatafrom the global phase 3 COMMODORE 1 and 2 studies evaluating crovalimab compared to eculizumab, a current standard of care in paroxysmal nocturnal hemoglobinuria (PNH), were presented at the European Hematology Association Hybrid Congress.
In the COMMODORE 2 study, 79.3% of participants randomized to be treated with crovalimab achieved hemolysis control from week five to week 25 compared with 79.0% withAstraZeneca Plc'sAZN Soliris (eculizumab).
AstraZeneca reported danicopan data showing that danicopan as an add-on to the standard of care C5 inhibitor therapy(ravulizumab) or(eculizumab) demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels and maintained disease control in PNH patients, compared to placebo plus establishedC5 inhibitor therapy
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors.
